Reperfusion injury
Drug research and approvals for reperfusion injury: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 34 studies of reperfusion injury are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 19 open orphan designations naming it.
- Recruiting worldwide: 34
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Minimal Sedation Versus Standard Continuous Sedation After Out-of-Hospital Cardiac ArrestNCT07895771 · Not applicable · University Medical Centre Ljubljana · starts Sep 22, 2026
- Cerebral Oximetry in Management of Post Cardiac ArrestNCT07829887 · Not applicable · University of Calgary · starts Oct 10, 2025
- Spectroscopic Assessment of Myocardial Oxygenation Changes in Pediatric Heart SurgeryNCT07785141 · Not reported · Spectrocor · starts Sep 17, 2026
- The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal TransplantationNCT07726134 · Not applicable · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · starts Sep 1, 2026
- Avoiding Recooling After Normothermic Machine Perfusion in Liver TransplantationNCT07692490 · Not applicable · The Mediterranean Institute for Transplantation and Advanced Specialized Therapies · starts Jul 7, 2026
- Perioperative Ursodeoxycholic Acid for Renal Protection in Adults Undergoing Partial Nephrectomy for Renal TumorsNCT07672860 · Phase 2 · Jinling Hospital, China · starts Jun 1, 2026
- Rapid Local Ischemic Postconditioning on Stroke After ThrombectomyNCT07598799 · Not applicable · Shanghai Jiao Tong University Affiliated Sixth People's Hospital · starts Oct 18, 2026
- Deceased Donor Kidney Storage at 10 Celsius Versus Conventional StorageNCT07385651 · Not applicable · Vanderbilt University Medical Center · starts Nov 18, 2024
- Remote Ischemic Preconditioning for Aute Type A Aortic Dissection SurgeryNCT07383909 · Not applicable · Fujian Medical University · starts Mar 29, 2026
Phase 3 11
- Nitric oxideSoluble guanylate cyclase activator
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- NitroglycerinSoluble guanylate cyclase activator
- BasiliximabInterleukin-2 receptor inhibitor
- ColchicineTubulin inhibitor
- DiltiazemVoltage-gated L-type calcium channel blocker
- SevofluraneGlycine receptor (alpha-1/beta) positive modulator
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- Fospropofol
- AcetylcysteineGlutathione precursor
- Nitric acid
Phase 2 12 of 16
- InfliximabTNF-alpha inhibitor
- EpoprostenolProstanoid IP receptor agonist
- ReparixinInterleukin-8 receptor A modulator
- MelatoninMelatonin receptor agonist
- Epoetin betaErythropoietin receptor agonist
- Thrombin
- Glutathione
- Vitamin e
- CyclosporineCyclophilin A modulator
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- EtanerceptTNF-alpha inhibitor
- TacrolimusFK506-binding protein 1A inhibitor
Phase 1 or earlier 6
- Estrogens, conjugatedEstrogen receptor agonist
- EsmololBeta-1 adrenergic receptor antagonist
- VardenafilPhosphodiesterase 5A inhibitor
- MilrinonePhosphodiesterase 3A inhibitor
- DapagliflozinSodium/glucose cotransporter 2 inhibitor
- OxygenEssential for cellular homeostasis
How its trials ended
256 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 54 whose ending is known, 26% met their primary endpoint, 33% missed it and 41% stopped early.
- Completed, result not reported11244%
- Status unknown5923%
- Ongoing3112%
- Missed its primary endpoint187%
- Stopped: other or unclear166%
- Met its primary endpoint145%
- Stopped: lack of efficacy21%
- Stopped: enrollment or feasibility21%
- Stopped: safety1<1%
- Stopped: sponsor or business decision1<1%
| Nov 6, 2023 | AlprostadilPrevention of ischemia/reperfusion injury resulting from solid organ transplantation. | Institut Georges Lopez | Designated |
| May 31, 2023 | N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-ThrPrevention of ischemia/reperfusion injury in kidney transplantation | Young Therapeutics, LLC | Designated |
| Dec 14, 2022 | Ketamine hydrochloridePrevention of ischemia/reperfusion injury during solid organ transplantation. | PharmaTher Inc. | Designated |
| Oct 17, 2022 | Synthetic polymer PEG conjugated to a phospholipid anchor…Prevention of ischemia reperfusion injury during solid organ transplantation | iCoat Medical AB | Designated |
| Feb 15, 2022 | BucillaminePrevention of ischemia-reperfusion injury during liver transplantation | Revive Therapeutics Inc. | Designated |
| Apr 27, 2021 | DimethyltryptaminePrevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation. | Sairiyo Therapeutics Inc. | Designated |
| Jul 10, 2020 | MitochondriaPrevention of ischemia-reperfusion injury during solid organ transplantation | cellvie Inc. | Designated |
| Nov 5, 2018 | CannabidiolPrevention of ischemia/reperfusion Injury resulting from solid organ transplantation | Revive Therapeutics Ltd. | Designated |
| May 2, 2017 | Macromolecular conjugate of heparin sodium on a polymer…Prevention of ischemia-reperfusion injury associated with solid organ tranplantation | Corline Biomedical AB | Designated |
| Oct 16, 2014 | Cardiotrophin-1Prevention of ischemia-reperfusion injury in kidney transplant recipients | Digna Biotech, S.L. | Designated |
| Aug 6, 2013 | Human HeminPrevention of ischemia reperfusion injury in patients undergoing solid organ transplantation | Borders Technology Management Ltd | Designated |
| Dec 12, 2011 | Humanized IgG4 monoclonal antibodyPrevention of ischemia/reperfusion injury associated with solid organ tranplantation | Neuramedy Co., Ltd. | Designated |
| Apr 18, 2011 | Methyl…Prevention of ischemia reperfusion injury associated wth solid organ transplantation | Endotis Pharma | Designated |
| Jan 29, 2010 | 17 amino acid peptidePrevention of ischemia reperfusion injury in the lung during lung tranplantation | Apeptico Forschung und Entwicklung GmbH (APEPTICO) | Designated |
| Oct 28, 2009 | DiannexinPrevention of ischemia-reperfusion injury in solid organ transplants | Astellas Pharma Global Development, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA